CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients
Introduction Rituximab (RTX) is a B cell-depleting agent approved for the treatment of granulomatosis with polyangiitis (GPA). RTX reduces antibody producing precursor plasma cells and inhibits B and T cells interaction. Infections related to T cell immunodeficiency are not infrequent during RTX tre...
| Main Authors: | , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
PeerJ Inc.
2016-09-01
|
| 丛编: | PeerJ |
| 主题: | |
| 在线阅读: | https://peerj.com/articles/2487.pdf |